• 11 min read
• Published on 15 August 2026
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 20 August 2026
Read article
Published on 20 August 2026
Read article
Published on 20 August 2026
Read article
Published on 20 August 2026
Read article
Published on 19 August 2026
Read article
The Profit Sacrifice. Digging into the Hims & Hers GLP-1 telehealth Q2 2026 data reveals a massive revenue beat, but the underlying HIMS stock earnings miss proves it's carrying a very real price tag. Growth at all costs. Period.
The Insurance Exodus. When traditional providers drop expensive branded treatments, patients don't just give up. They're immediately seeking cheaper alternatives. This coverage gap is fuelling compounded semaglutide demand, pushing capital into GLP-1 telehealth stocks that can actually absorb these displaced patients.
The Digital Rush. The ambitious Hims revenue forecast 2026 suggests the runway here could be massive. Modern traders are exploring telehealth weight loss investing for portfolio building and diversification, using a regulated broker to access commission-free trading and buy fractional shares with small amounts.
The FDA Trap. The entire compounding business model rests on a temporary regulatory loophole. If officials declare the drug shortages over, this lucrative revenue stream might vanish overnight. Every investment carries risk, making AI-driven research and real-time insights absolutely vital before you commit cash.
I have been watching the telehealth sector for a fair few years now, and if there is one universal truth I have picked up, it is that the market absolutely craves a simple narrative. Hims & Hers Health, however, stubbornly refuses to provide one. Their second-quarter results landed recently, and they were exactly the sort of messy, split-decision affair that keeps analysts arguing in circles for weeks. Revenue beat expectations quite comfortably. Earnings per share, predictably, missed the mark entirely.
To me, this quarter was the corporate equivalent of a solid middle-order innings in a Test match. There are undeniably runs on the board, but we all saw a few edgy shots that sailed dangerously close to the slips. The company even raised its full-year revenue guidance to an eye-watering $3.1 billion to $3.3 billion. That implies management expects a second half of the year that is significantly stronger than the first. It is a wildly ambitious target, but ambition alone does not magically translate into shareholder returns.
We need to look much deeper than the headline figures.
Revenue is vanity, and profit is sanity, but in the brutal world of digital health, subscriber growth is the absolute only number that dictates survival.
Both the revenue beat and the earnings miss matter immensely, and it would be a foolish investor who dismisses either one of them. The revenue surge confirms that patient demand for the platform's services is growing at a blistering pace. People genuinely want access to personalised weight management, and they are willing to pay for the convenience. Yet, the earnings miss is a stark reminder that Hims & Hers is still spending aggressively to capture that fleeting digital demand. That spending has a very real, very heavy cost attached to it.
The true engine behind this subscriber growth is barely concealed at this point. It is the exploding demand for GLP-1 weight-loss drugs. We are currently witnessing one of the most profound shifts in consumer healthcare behaviour in a generation. Patients are desperate for these treatments, but the conventional medical pathways are brittle, ossified, and prohibitively expensive for the average citizen.
This structural advantage for telehealth platforms has been practically gifted to them by the broader healthcare system. When traditional insurers pull back coverage for wildly expensive branded GLP-1 drugs, the patients do not simply shrug their shoulders and stop wanting to lose weight. They actively look for workarounds. Take Cigna as a prime example. Their highly publicised decision to drop coverage for branded weight-loss medications for their own employees is a perfect case study. When corporate coverage evaporates, frustrated patients are funnelled directly toward direct-to-consumer digital platforms.
This precise dynamic is captured beautifully in The GLP-1 Insurance Gap Reshaping Weight Care in 2026. Traditional insurance providers are retreating from the massive costs, and platforms equipped with slick digital infrastructure and ready prescription fulfilment are perfectly positioned to absorb that redirected demand. Compounded semaglutide, the active ingredient found in Novo Nordisk's Wegovy, has been a massive growth driver here. Compounding pharmacies are legally permitted to produce versions of drugs that are officially listed as being in shortage, and Hims & Hers has built a formidable, highly lucrative business segment around this specific legal provision.
I think investors need to be brutally honest with themselves about the tension between growth and profitability in this particular stock. The pattern of beating on top-line revenue whilst missing on core earnings is not some unfortunate accounting accident. It reflects a very deliberate, Silicon Valley style strategic choice. You spend thousands of pounds now to acquire the subscriber, and you simply pray you can monetise them at a later date. It is a familiar playbook, and it certainly can work, but it requires investors to accept a long, painful period of compressed profitability in exchange for the mere promise of future operating leverage.
The underlying mechanism is entirely straightforward. Acquiring a new patient costs a small fortune in digital marketing spend, clinical infrastructure, and complex fulfilment logistics. However, once that subscriber is safely locked into the digital ecosystem, the incremental cost of actually serving them drops significantly. As the user base scales up into the millions, those heavy fixed costs are spread across more paying customers, and profit margins should theoretically improve. That is the rosy, optimistic operating leverage argument the bullish analysts will pitch to you.
But we must ask ourselves at exactly what scale that leverage actually materialises. If management is hinting at a path to meaningful margin expansion only when they approach three million active subscribers, you have to critically assess whether that milestone is even credible within a sensible timeframe.
The history of the digital health sector is littered with painful cautionary tales.
Growth at all costs is a dangerously seductive game, and the financial bill eventually comes due.
I vividly remember watching Teladoc Health play this exact game a few years ago. They chased aggressive user growth at the expense of profitability for years, assuming the market would infinitely reward scale. Ultimately, that flawed strategy resulted in staggering write-downs and a dramatic de-rating of the stock that left retail investors nursing incredibly heavy losses. While the Hims & Hers direct-to-consumer business model is structurally different, the warning embedded in that history remains highly relevant. Management will need to definitively prove that their subscriber acquisition costs are actually falling as the platform matures.
We cannot properly discuss this space without looking at the pharmaceutical heavyweights, Eli Lilly and Novo Nordisk. For these massive, entrenched companies, the recent financial results from Hims & Hers are not simply a story about a plucky digital competitor. They are a glaring, unignorable volume signal. Rising demand for GLP-1 treatments, whether accessed through expensive branded pens or compounded alternatives in a glass vial, reflects a rapidly expanding overall market. To the extent that telehealth platforms are aggressively normalising these treatments, you could easily argue they are indirectly expanding the total addressable market for Eli Lilly's Zepbound and Novo Nordisk's Wegovy.
The dynamic becomes incredibly complicated when we look at the profit margins. Compounded semaglutide is, by definition, sold at a steep discount to the branded Wegovy product. Therefore, every single patient who accesses their treatment through a cheaper compounding route represents a lost revenue opportunity that Novo Nordisk simply does not capture. At a large enough scale, this rogue alternative supply chain could represent a meaningful headwind to the pricing power of the big pharmaceutical firms, even if overall market volumes continue to swell.
Let us look closely at Eli Lilly for a moment. Their highly effective active ingredient, tirzepatide, is also subject to these compounding exemptions during periods of official national shortage. However, Eli Lilly has not been sitting idly by while digital clinics eat their lunch. They have been incredibly active in pursuing legal enforcement, firing off aggressive cease and desist letters to compounders and medical spas. In the early days of this boom, the alternative market was a chaotic gold rush. Then, the legal letters started flying, and the entire landscape suddenly shifted. There are clear, undeniable signs that regulatory and legal pressure on these alternative supply chains is increasing rapidly.
This brings us to the most critical point of all, and it is one that many optimistic investors conveniently choose to ignore. The end of these compounding exemptions is perhaps the most absolute, binary risk in this entire investment thesis. Compounding pharmacies are currently operating in a fragile legal grey area that only exists because the FDA officially lists these blockbuster drugs as being in shortage. Unsurprisingly, Eli Lilly and Novo Nordisk are currently pouring billions of dollars into aggressively expanding their manufacturing capacity to resolve these exact shortages.
If the FDA moves decisively to declare the shortages over, the legal basis for compounded semaglutide and tirzepatide vanishes into thin air. Hims & Hers could easily lose its most lucrative growth driver virtually overnight. Naturally, that regulatory outcome would be a material positive for the big pharmaceutical companies, as thousands of stranded patients would be suddenly redirected back toward their branded, higher-margin drugs.
Conversely, if these compounding exemptions persist or even expand due to lingering supply chain issues, the margin pressure on the branded drug makers might only intensify. Both scenarios are entirely live possibilities, and they will dictate the future winners of this sector. Investing in this space is absolutely not a safe bet, and any capital deployed here is subject to severe regulatory whiplash. You might see significant upside if the telehealth adoption curve continues to steepen, but you could just as easily face steep, painful losses if the regulatory hammer finally falls. You must weigh these outcomes carefully, because in the volatile intersection of digital health and federal regulation, certainty is the only thing that is truly in short supply.
View the full Basket:The GLP-1 Insurance Gap Reshaping Weight Care in 2026
View the full Basket:The GLP-1 Insurance Gap Reshaping Weight Care in 2026
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 20 August 2026
Read article
Published on 20 August 2026
Read article
Published on 20 August 2026
Read article
Published on 20 August 2026
Read article
Published on 19 August 2026
Read article